Drug data last refreshed 2h ago · AI intelligence enriched 2w ago
MPI DMSA KIDNEY REAGENT is a diagnostic imaging agent administered via injection used for renal scintigraphy and kidney function assessment. It is a small-molecule radiopharmaceutical that localizes in the kidneys to enable visualization and evaluation of renal perfusion and function. The mechanism involves binding to renal tubular cells, allowing clinicians to assess kidney morphology and differential renal function.
As LOE approaches, commercial teams face contraction; expect focus on defending market share against generic/biosimilar entrants and managing decline in headcount.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on MPI DMSA offers limited growth but provides deep expertise in diagnostic imaging commercialization and mature-product management. Professionals should expect focus on defensive strategies, cost management, and eventual transition to adjacent opportunities as LOE approaches.
Worked on MPI DMSA KIDNEY REAGENT at GE HealthCare? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.